Comparative Bioavailability of Intranasal Epinephrine
Status:
COMPLETED
Trial end date:
2024-02-05
Target enrollment:
Participant gender:
Summary
A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults
Phase:
PHASE1
Details
Lead Sponsor:
Nasus Pharma
Collaborators:
Hadassah Medical Organization Medistat Ltd., Israel Pharma Medica Research, Inc.